ライフサイエンスコーパス: bridge to transplantation

1 required ECMO and 22 (4.1%) required MV as a bridge to transplantation.

2 primary indication for MCS therapy supported bridge to transplantation.

3 standard in the United States for pediatric bridge to transplantation.

4 uous-flow left ventricular assist device for bridge to transplantation.

5 t placement of the Micromed DeBakey VAD as a bridge to transplantation.

6 acute liver failure to provide stability and bridge to transplantation.

7 in children until improvement occurs or as a bridge to transplantation.

8 icular assist device (LVAD) is inserted as a bridge to transplantation.

9 cted patients who received this therapy as a bridge to transplantation.

10 e oxygenation or mechanical ventilation as a bridge to transplantation.

11 Nine patients were successfully "bridged" to transplantation.

12 tion pumps is a well-established therapy for bridging to transplantation.

13 The indications for LVAS support were bridge to transplantation (54%) or destination therapy (

14 The cohort was predominantly bridge-to-transplantation (67%), with median age of 59 y

15 sed significantly in recent years, both as a bridge to transplantation and as destination therapy in

16 Patients enrolled into the HMII bridge to transplantation and destination therapy trials

17 Traditionally viewed as a bridge to transplantation and more recently as a destina

18 They were successfully bridged to transplantation and received heart transplant

19 rrelation between the proportion of patients bridged to transplantation and the proportion of patient

20 trated with LVAD unloading alone in patients bridged to transplantation and those occurring in the my

21 % had an ischemic cardiomyopathy, 87.7% were bridge to transplantation, and median length of support

22 rs, 87.7% of the implants were intended as a bridge to transplantation, and median length of support

23 nts with advanced heart failure, either as a bridge to transplantation, as destination therapy, or in

24 ve review of patients receiving a mechanical bridge to transplantation at Columbia Presbyterian Hospi

25 tricular assist systems (LVASs) are used for bridging to transplantation, bridging to myocardial impr

26 horatec Corporation, Pleasanton, California) bridge to transplantation (BTT) (n = 281) and destinatio

27 ere liver trauma (SLT), in ALF patients as a bridge to transplantation (BTT), and as definitive thera

28 g Administration approved the HM II LVAD for bridge to transplantation (BTT).

29 imed to evaluate the cost-effectiveness of a bridge-to-transplantation (BTT)-VAD approach relative to

30 This initial experience suggests that bridging to transplantation can be successfully approach

31 LVRS should not be easily considered as a bridge to transplantation for all lung transplant candid

32 tients underwent implantation of a HMII as a bridge to transplantation from March 2005 to March 2007.

33 ch devices in the short and medium term as a bridge to transplantation has led to their evaluation as

34 experience with inpatient LVAD support as a bridge to transplantation has proved the efficacy of suc

35 tion of left ventricular assist devices as a bridge-to-transplantation have resulted in HLA sensitiza

36 Data on VADs as a bridge to transplantation in children are limited.

37 he adjunct efficacy of Sorafenib to Y90 as a bridge to transplantation in hepatocellular carcinoma (H

38 us inotropic therapy can be safely used as a bridge to transplantation in pediatric patients.

39 portocaval shunting has been described as a bridge to transplantation in the most severe cases, as w

40 l date of the first continuous-flow LVAD for bridge to transplantation in the United States (2008).

41 f left ventricular assist devices (LVADs) as bridges to transplantation is successful, the issue of p

42 ), which was originally used clinically as a bridge to transplantation, may also be used as destinati

43 hospital after LVAD implantation in the HMII bridge to transplantation (n = 405) and destination ther

44 ut severe comorbidity for whom dialysis is a bridge to transplantation or a long-term maintenance tre

45 , and January 1, 2010, as part of either the bridge to transplantation or destination therapy trials

46 ective of the intended goal of pump support (bridge to transplantation or destination therapy).

47 r bridge to myocyte recovery, as well as for bridge to transplantation or long-term support.

48 Eight-two patients (55%) were either bridged to transplantation, recovery or are ongoing and

49 c reserve, the shunt was used as a long-term bridge to transplantation (shunt group 1).

50 were scheduled for placement of an LVAD as a bridge to transplantation underwent bone marrow aspirati

51 (HR=2.011, 95% CI=1.069-3.784; P=0.030) as a bridge to transplantation was independently associated w

52 nths); 28% had cardiomyopathy; and in 38%, a bridge to transplantation was intended at ECMO initiatio

53 o had received a total artificial heart as a bridge to transplantation were 86 and 64 percent.

54 us eliminating problems commonly seen in the bridge to transplantation with left ventricular and bive

55 In the recent era (2000 to 2003), successful bridge to transplantation with VAD was achieved in 86% o

56 Pediatric heart transplant patients (n=106) bridged to transplantation with EXCOR were compared with

57 Bridging to transplantation with an implantable LVAD imp

58 dvanced heart failure patients who are being bridged to transplantation, without evidence of detrimen